Your browser doesn't support javascript.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Yamasoba, Daichi; Kimura, Izumi; Nasser, Hesham; Morioka, Yuhei; Nao, Naganori; Ito, Jumpei; Uriu, Keiya; Tsuda, Masumi; Zahradnik, Jiri; Shirakawa, Kotaro; Suzuki, Rigel; Kishimoto, Mai; Kosugi, Yusuke; Kobiyama, Kouji; Hara, Teppei; Toyoda, Mako; Tanaka, Yuri L; Butlertanaka, Erika P; Shimizu, Ryo; Ito, Hayato; Wang, Lei; Oda, Yoshitaka; Orba, Yasuko; Sasaki, Michihito; Nagata, Kayoko; Yoshimatsu, Kumiko; Asakura, Hiroyuki; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Kuramochi, Jin; Seki, Motoaki; Fujiki, Ryoji; Kaneda, Atsushi; Shimada, Tadanaga; Nakada, Taka-Aki; Sakao, Seiichiro; Suzuki, Takuji; Ueno, Takamasa; Takaori-Kondo, Akifumi; Ishii, Ken J; Schreiber, Gideon; Sawa, Hirofumi; Saito, Akatsuki; Irie, Takashi; Tanaka, Shinya; Matsuno, Keita; Fukuhara, Takasuke; Ikeda, Terumasa; Sato, Kei.
  • Yamasoba D; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Medicine, Kobe University, Kobe, Japan.
  • Kimura I; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Nasser H; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Morioka Y; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Nao N; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Tsuda M; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Zahradnik J; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Suzuki R; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Kishimoto M; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan; Graduate School of Pharmaceutical Scienc
  • Kobiyama K; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hara T; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Toyoda M; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Tanaka YL; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Butlertanaka EP; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Shimizu R; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Ito H; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Wang L; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Oda Y; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Orba Y; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Sasaki M; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nagata K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Yoshimatsu K; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Asakura H; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Nagashima M; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Sadamasu K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Yoshimura K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Kuramochi J; Interpark Kuramochi Clinic, Utsunomiya, Japan.
  • Seki M; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Fujiki R; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kaneda A; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Shimada T; Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Nakada TA; Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Sakao S; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Suzuki T; Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Ueno T; Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Ishii KJ; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Schreiber G; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Sawa H; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sap
  • Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Chiba, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan. Electronic address: sakatsuki@cc.m
  • Irie T; Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Electronic address: tirie@hiroshima-u.ac.jp.
  • Tanaka S; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address: tanaka@med.hokudai.ac.jp.
  • Matsuno K; One Health Research Center, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo,
  • Fukuhara T; Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Electronic address: fukut@pop.med.hokudai.ac.jp.
  • Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. Electronic address: ikedat@kumamoto-u.ac.jp.
  • Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University
Cell ; 185(12): 2103-2115.e19, 2022 06 09.
Article in English | MEDLINE | ID: covidwho-1814233
ABSTRACT
Soon after the emergence and global spread of the SARS-CoV-2 Omicron lineage BA.1, another Omicron lineage, BA.2, began outcompeting BA.1. The results of statistical analysis showed that the effective reproduction number of BA.2 is 1.4-fold higher than that of BA.1. Neutralization experiments revealed that immunity induced by COVID vaccines widely administered to human populations is not effective against BA.2, similar to BA.1, and that the antigenicity of BA.2 is notably different from that of BA.1. Cell culture experiments showed that the BA.2 spike confers higher replication efficacy in human nasal epithelial cells and is more efficient in mediating syncytia formation than the BA.1 spike. Furthermore, infection experiments using hamsters indicated that the BA.2 spike-bearing virus is more pathogenic than the BA.1 spike-bearing virus. Altogether, the results of our multiscale investigations suggest that the risk of BA.2 to global health is potentially higher than that of BA.1.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.04.035

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.04.035